[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2019, CA Cancer J Clin 69(1) (2019) 7-34.
[2] Y. Mao, Z. Fu, Y. Zhang, L. Dong, Y. Zhang, Q. Zhang, X. Li, J. Liu, A seven-lncRNA signature predicts overall survival in esophageal squamous cell carcinoma, Sci Rep 8(1) (2018) 8823.
[3] R.J. Zeng, C.W. Zheng, J.E. Gu, H.X. Zhang, L. Xie, L.Y. Xu, E.M. Li, RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes, Mol Oncol 13(9) (2019) 2010-2030.
[4] L.Y. Chu, Y.H. Peng, X.F. Weng, J.J. Xie, Y.W. Xu, Blood-based biomarkers for early detection of esophageal squamous cell carcinoma, World J Gastroenterol 26(15) (2020) 1708-1725.
[5] Z. Wang, M.Q. Yang, L. Lei, L.R. Fei, Y.W. Zheng, W.J. Huang, Z.H. Li, C.C. Liu, H.T. Xu, Overexpression of KRT17 promotes proliferation and invasion of non-small cell lung cancer and indicates poor prognosis, Cancer Manag Res 11 (2019) 7485-7497.
[6] L. Yang, S. Zhang, G. Wang, Keratin 17 in disease pathogenesis: from cancer to dermatoses, J Pathol 247(2) (2019) 158-165.
[7] J. Wu, H. Xu, H. Ji, B. Zhai, J. Zhu, M. Gao, H. Zhu, X. Wang, Low Expression of Keratin17 is Related to Poor Prognosis in Bladder Cancer, Onco Targets Ther 14 (2021) 577-587.
[8] H. Hua, Q. Kong, H. Zhang, J. Wang, T. Luo, Y. Jiang, Targeting mTOR for cancer therapy, J Hematol Oncol 12(1) (2019) 71.
[9] A.K. Murugan, mTOR: Role in cancer, metastasis and drug resistance, Semin Cancer Biol 59 (2019) 92-111.
[10] B. Magnuson, B. Ekim, D.C. Fingar, Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks, Biochem J 441(1) (2012) 1-21.
[11] S. Sridharan, A. Basu, Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer, Int J Mol Sci 21(4) (2020).
[12] H. Shen, G.C. Wang, X. Li, X. Ge, M. Wang, Z.M. Shi, V. Bhardwaj, Z.X. Wang, R.G. Zinner, S.C. Peiper, A.E. Aplin, B.H. Jiang, J. He, S6K1 blockade overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer, Oncogene 39(49) (2020) 7181-7195.
[13] J.R. Wisniewski, A. Zougman, N. Nagaraj, M. Mann, Universal sample preparation method for proteome analysis, Nat Methods 6(5) (2009) 359-62.
[14] D. Li, X.F. Ni, H. Tang, J. Zhang, C. Zheng, J. Lin, C. Wang, L. Sun, B. Chen, KRT17 Functions as a Tumor Promoter and Regulates Proliferation, Migration and Invasion in Pancreatic Cancer via mTOR/S6k1 Pathway, Cancer Manag Res 12 (2020) 2087-2095.
[15] H. Yang, L. Hu, Z. Liu, Y. Qin, R. Li, G. Zhang, B. Zhao, C. Bi, Y. Lei, Y. Bai, Inhibition of Gli1-mediated prostate cancer cell proliferation by inhibiting the mTOR/S6K1 signaling pathway, Oncol Lett 14(6) (2017) 7970-7976.
[16] Z. Xie, T. Li, B. Huang, S. Liu, L. Zhang, Q. Zhang, Semaphorin 3F Serves as a Tumor Suppressor in Esophageal Squamous Cell Carcinoma and is Associated With Lymph Node Metastasis in Disease Progression, Technol Cancer Res Treat 19 (2020) 1533033820928117.
[17] Y. Yang, H. Ge, Effective combinations of radiotherapy and immunotherapy in the treatment of esophageal squamous cell carcinoma, Future Oncol 16(31) (2020) 2537-2549.
[18] C.H. Chiang, C.C. Wu, L.Y. Lee, Y.C. Li, H.P. Liu, C.W. Hsu, Y.C. Lu, J.T. Chang, A.J. Cheng, Proteomics Analysis Reveals Involvement of Krt17 in Areca Nut-Induced Oral Carcinogenesis, J Proteome Res 15(9) (2016) 2981-97.
[19] X. Yan, C. Yang, W. Hu, T. Chen, Q. Wang, F. Pan, B. Qiu, B. Tang, Knockdown of KRT17 decreases osteosarcoma cell proliferation and the Warburg effect via the AKT/mTOR/HIF1alpha pathway, Oncol Rep 44(1) (2020) 103-114.
[20] M. Dong, Z. Dong, X. Zhu, Y. Zhang, L. Song, Long non-coding RNA MIR205HG regulates KRT17 and tumor processes in cervical cancer via interaction with SRSF1, Exp Mol Pathol 111 (2019) 104322.
[21] M. Chivu-Economescu, D.L. Dragu, L.G. Necula, L. Matei, A.M. Enciu, C. Bleotu, C.C. Diaconu, Knockdown of KRT17 by siRNA induces antitumoral effects on gastric cancer cells, Gastric Cancer 20(6) (2017) 948-959.
[22] R. Lou, P. Tang, K. Ding, S. Li, C. Tian, Y. Li, S. Zhao, Y. Zhang, W. Shui, Hybrid Spectral Library Combining DIA-MS Data and a Targeted Virtual Library Substantially Deepens the Proteome Coverage, iScience 23(3) (2020) 100903.
[23] B.C. Searle, K.E. Swearingen, C.A. Barnes, T. Schmidt, S. Gessulat, B. Kuster, M. Wilhelm, Generating high quality libraries for DIA MS with empirically corrected peptide predictions, Nat Commun 11(1) (2020) 1548.
[24] M. Moschetta, A. Reale, C. Marasco, A. Vacca, M.R. Carratu, Therapeutic targeting of the mTOR-signalling pathway in cancer: benefits and limitations, Br J Pharmacol 171(16) (2014) 3801-13.
[25] H. Populo, J.M. Lopes, P. Soares, The mTOR signalling pathway in human cancer, Int J Mol Sci 13(2) (2012) 1886-918.